Click here to close now.




















Welcome!

News Feed Item

Serenus Biotherapeutics Strengthens Leadership With Appointments to Board and Management

Company Adds Team Members With Extensive Knowledge of Sub-Saharan African Markets and Global Biopharmaceutical Industry

SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA -- (Marketwired) -- 07/24/14 -- Serenus Biotherapeutics, Inc., a specialty biopharmaceutical company bridging the divide between the world's leading pharmaceutical markets and the growing demand for access to innovative therapies in the emerging nations of Sub-Saharan Africa, today announced appointments to its board of directors and senior management team.

The company named to its board of directors Sbu Luthuli, former Chairman of Cipla Medpro; Dr. Nigel Fleming, founder and former Chairman of Athena Diagnostics; and Kazuhiro Umeda, former President of JAIC Singapore, Indonesia, and Thailand.

In addition, the company made appointments to its executive management team. It named Moosa Areff, who most recently served as CEO of Ranbaxy South Africa's Sonke Pharmaceuticals subsidiary, as its Chief Operating Officer. It also named Andrew de Pão, who served as Head of Marketing of the Prescription Division at Cipla South Africa, as its Chief Business Officer; and Nahum Johnson, former Business Unit Manager - State Institutional and Government at Cipla Medpro, as Director State and Institutional Business.

"We are pleased to have attracted a distinguished group of board members to guide us as we begin to implement our plans, enter into new partnerships, and grow our company," says Dr. Menghis Bairu, founder, Chairman, and CEO of Serenus Biotherapeutics. "The additions we have made to our executive team give us the people on the ground with intimate knowledge of the Sub-Saharan African landscape needed to execute on our strategy."

Mr. Luthuli noted that the appointments come as the Sub-Saharan African market is experiencing rapid economic development, the emergence of a burgeoning middle class, and a marked shift in disease profiles.

"The Sub-Saharan African pharmaceutical market is growing rapidly as lifestyle changes are driving a shift in disease burden from infectious to chronic diseases. Nevertheless, access to needed innovative therapeutics is still limited today," says Mr. Luthuli. "Serenus offers an African access platform that uniquely positions it to serve as a partner of choice for biopharmaceutical companies with innovative therapies in developed markets that appreciate the opportunities in the emerging markets of Sub-Saharan Africa, but may not have the expertise or networks needed to address the complexity of doing business in the region."

Below are bios of the Serenus Biotherapeutics appointees announced today.

Sbu Luthuli
Member of the Board of Directors
Mr. Luthuli is the CEO and Principal Officer of the Eskom Pension and Provident Fund, one of the largest self-administered pension funds in South Africa with assets under management in excess of $10.4 billion (R110 billion). Prior to this, he served as CEO of Ithala Bank Limited, where he transformed and grew the bank through the launch of new products and the introduction of electronic banking. He is a director at Telkom SA Limited and also serves as the Vice Chairman of Batseta, an industry organization representing pension fund trustees and principal officers. He was involved with Cipla Medpro (formerly Enaleni Pharmaceuticals Limited) for ten years and served as Chairman of the Board of Directors until its sale to Cipla India in 2013.

Dr. Nigel Fleming
Member of the Board of Directors
Dr. Fleming is founder and Chairman of G2B Pharma Inc., which is reformulating off-patent drugs to significantly improve their safety or efficacy. He founded and served as Chairman of Athena Diagnostics, a leading provider of advanced neurodiagnostic tests, used for neuromuscular and metabolic diseases. Dr. Fleming has served on various boards, including Exemplar, Impax Labs, Genmedica Therapeutics, A-Cube, Minoryx Therapeutics (as Chairman), and the Institute for OneWorld Health. He has also served as a Lecturer at Harvard Medical School. He earned his Ph.D. in Clinical Biochemistry from Cambridge University, and completed a post-doctoral fellowship at Boston University Medical School.

Kazuhiro Umeda
Member of the Board of Directors
Mr. Kazuhiro in 2005 joined Japan Asia Investment Co. Ltd., one of Japan's largest Venture Capital Firms. He served as Head of the CEO's Office, as well as President, heading up the Japan Asia Investment Company's Singapore, Indonesia, and Thailand office. He also founded Apricot, a natural food and drink company as a vehicle for commonly used pharmaceuticals, a revolutionary approach for pharmaceutical dosing. His early career included sales promotion for Daiichi Pharmaceuticals Group of Japan. He earned a master's and bachelor's degree in life sciences from the Tokyo University of Pharmacy and Life Sciences.

Moosa Areff
Chief Operating Officer
Mr. Areff comes to Serenus with 18 years of experience in the biopharmaceutical industry, starting as a sales representative and ultimately rising to become CEO at Ranbaxy South Africa's Sonke Pharmaceuticals. During his career he led the team that marketed and sold the first South African over-the-counter product in the Middle East and Africa and also negotiated and sold the first voluntarily licensed antiretroviral products into Sub-Saharan Africa. Mr. Areff served as Aspen Pharmacare's sales and marketing country manager for Nigeria, Uganda, and Libya for the launch of Gilead Sciences' Viread and Truvada. He also served as senior executive of new business development for Cipla Medpro and led commercial due diligence of the sale of Cipla Medpro to Enaleni Pharma. He has a diploma in journalism from Damelin College.

Andrew de Pão
Chief Business Officer
Mr. de Pão served as Head of Marketing for the Prescription Division at Cipla South Africa, as well as the commercial lead for Cipla South Africa Biosimilars Task Team. While there, he spearheaded the development and implementation of peri-, pre-, and post-launch clinical, marketing and communication campaigns across all prescription and OTX disease categories. Prior to joining Cipla South Africa, Mr. de Pão held a Healthcare Communications Consultant and Directors position at Publicis Global Healthcare Communications Group in the United Kingdom, where his team was involved in development of Global Brand Communication Strategies for various multinational pharmaceutical companies and provided corporate brand positioning and development and execution of digital and social media programs. He holds a Bachelor's in Physiology and Biochemistry and a Master's in Physiology from the University of Stellenbosch, South Africa.

Nahum Johnson
Director State and Institutional Business
Mr. Johnson has 20 years of experience in the biopharmaceutical industry. He most recently served as Pharma Unit Manager-State Institutional and Government at Cipla Medpro. Prior to that, he served as Key Account Manager-Public Sector for Adcock Ingram. He has a Bachelor's in Biochemistry from the University of the Western Cape, a postgraduate degree in Management Development Practice from the Department of Management Sciences, Business Graduate School UNISA; and is currently completing a Master's in Information Systems Knowledge Management.

About Serenus Biotherapeutics
Serenus Biotherapeutics is a privately held specialty biopharmaceutical company that specializes in late-stage drug development, in-licensing, registering, and commercializing therapies approved in the United States, Europe, and Japan to address unmet medical needs with high regional prevalence in the Sub-Saharan African market. For more information, please visit www.serenusbio.com

Contact:
Daniel Levine
Levine Media Group
(510) 280-5405
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"Alert Logic is a managed security service provider that basically deploys technologies, but we support those technologies with the people and process behind it," stated Stephen Coty, Chief Security Evangelist at Alert Logic, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
"ProfitBricks was founded in 2010 and we are the painless cloud - and we are also the Infrastructure as a Service 2.0 company," noted Achim Weiss, Chief Executive Officer and Co-Founder of ProfitBricks, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
"We specialize in testing. DevOps is all about continuous delivery and accelerating the delivery pipeline and there is no continuous delivery without testing," noted Marc Hornbeek, Sr. Solutions Architect at Spirent Communications, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
In his keynote at 16th Cloud Expo, Rodney Rogers, CEO of Virtustream, discussed the evolution of the company from inception to its recent acquisition by EMC – including personal insights, lessons learned (and some WTF moments) along the way. Learn how Virtustream’s unique approach of combining the economics and elasticity of the consumer cloud model with proper performance, application automation and security into a platform became a breakout success with enterprise customers and a natural fit f...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
"We have been in business for 21 years and have been building many enterprise solutions, all IT plumbing - server, storage, interconnects," stated Alex Gorbachev, President of Intelligent Systems Services, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.